Boston Scientific (BSX) Cost of Revenue (2009 - 2026)

Boston Scientific has disclosed Cost of Revenue across 18 years of filings, most recently posting $1.6 billion for Q2 2026.

• In Q2 2026, Cost of Revenue fell 2.63% year-over-year to $1.6 billion; the TTM figure through Jun 2026 stood at $6.3 billion (up 7.62% YoY), while the FY2025 annual figure was $6.2 billion, up 18.34% from the prior year.
• Cost of Revenue came in at $1.6 billion for Q2 2026 at Boston Scientific, roughly flat from $1.6 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $1.6 billion in Q2 2025 to a low of $955.0 million in Q1 2022.
• Average Cost of Revenue over 5 years is $1.3 billion, with a median of $1.2 billion recorded in 2024.
• Year-over-year, Cost of Revenue gained 28.9% in 2025 and dropped 2.63% in 2026.
• Over 5 years, Cost of Revenue stood at $1.0 billion in 2022, then grew by 13.45% to $1.1 billion in 2023, then increased by 27.81% to $1.5 billion in 2024, then increased by 9.69% to $1.6 billion in 2025, then retreated by 0.87% to $1.6 billion in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $1.6 billion in Q2 2026, $1.6 billion in Q1 2026, and $1.6 billion in Q4 2025.